Solid Biosciences SLDB
NASDAQ SLDB
$6.85 -0.13 (-1.86%)
At close: Oct 2, 2026 · 4:00 PM EDT

Solid Biosciences (SLDB) Gains from Sales and Divestitures (2018 - 2021)

Updated

Solid Biosciences (SLDB) reported Gains from Sales and Divestitures of -$374,000 for FY2023.

Analysis

Solid Biosciences (SLDB) Gains from Sales and Divestitures (2018 - 2021) Analysis & Trends

Dating back to FY2018, Solid Biosciences' Gains from Sales and Divestitures record includes 4 years.

  • According to Business Quant data, Gains from Sales and Divestitures came in at -$92,000 in FY2021 and -$2,000 in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Solid Biosciences 984.27 Mn 984.27 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -83,000.00
Sep 30, 2021 -6,000.00
Mar 31, 2021 -3,000.00
Dec 31, 2018 -7,000.00
Sep 30, 2018 9,000.00
API Access

Solid Biosciences Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=SLDB&period=max&api_key=YOUR_API_KEY